Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 influenza season
Open accessThe DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020-21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020-21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture-based IIV4 (ccIIV4) or RIV4.The 2020-21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html.This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020-21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)-licensed indications. Updates and other information are available from CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“From placebo-controlled clinical trial data, there is no evidence of increased calcitonin or C-cell neoplasia in humans”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1811]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Self-citationFiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 2,076
Self-citationGrohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
Self-citationPandemic 2009 Influenza A(H1N1) Virus Illness Among Pregnant Women in the United States
Siston, A. M. (2010) · JAMA · doi:10.1001/jama.2010.479 · Cited by 1,034
Self-citation(2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03793.x · Cited by 957
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315727 · Cited by 876 · cited 1×
“Fluzone High-Dose (HD-IIV3) met prespecified criteria for superior efficacy against laboratory-confirmed influenza compared with that of standard-dose Fluzone (SD-IIV3) in a randomized trial conducted over two seasons (2011–12 and 2012–13) among 31,989 persons aged ≥65 years (53,60,61).”
BackgroundThe Underrecognized Burden of Influenza in Young Children
Poehling, K. A., Edwards, K. M., Weinberg, G. A., Szilagyi, P., Staat, M. A., Iwane, M. K., Bridges, C. B., Grijalva, C. G., Zhu, Y., Bernstein, D. I., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054869 · Cited by 872
Shefer, A. M., & Atkinson, W. W. (2011) · Cited by 665
Pearson, M. L., Bridges, C. B., & Harper, S. A. (2006) · PsycEXTRA Dataset · doi:10.1037/e506932006-001 · Cited by 529
Patel, A., Jernigan, D. B., 2019-nCoV CDC Response Team, 2019-nCoV CDC Response Team, Abdirizak, F., Abedi, G., Aggarwal, S., Albina, D., Allen, E., Andersen, L., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6905e1 · Cited by 449
Self-citation
Research works printed but not linked: 3
- Food and Drug Administration. Clinical review: Fluad. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015.
- Food and Drug Administration. Clinical review: Fluzone high-dose. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014.
- Food and Drug Administration. Clinical review: Fluad Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020.
Cited by
Olsen, S. J., Winn, A. K., Budd, A. P., Prill, M. M., Steel, J., Midgley, C. M., Kniss, K., Burns, E., Rowe, T., Foust, A., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7029a1 · Cited by 600
Self-citationOlsen, S. J., Azziz-Baumgartner, E., Budd, A. P., Brammer, L., Sullivan, S., Pineda, R. F., Cohen, C., & Fry, A. M. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6937a6 · Cited by 579
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Grohskopf, L. A., Alyanak, E., Ferdinands, J. M., Broder, K. R., Blanton, L. H., Talbot, H. K., & Fry, A. M. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7005a1 · Cited by 360
Self-citation
Metadata
- Authors
- Grohskopf, L. A., Alyanak, E., Broder, K. R., Blanton, L. H., Fry, A. M., Jernigan, D. B., & Atmar, R. L.
- Affiliations
- National Center for Immunization and Respiratory Diseases (US)
- Battelle (US)
- Centers for Disease Control and Prevention (US)
- Baylor College of Medicine (US)
- Corresponding author
- Grohskopf, Lisa A.
- Venue
- MMWR. Recommendations and Reports
- Published
- 2020-08-21
- Volume
- 69
- Issue
- 8
- Pages
- 1-24
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- PMC
- PMC7439976
- OpenAlex
- W4211031111
- Cited by
- 332
- References
- 88
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 33 · 2023: 42 · 2022: 92 · 2021: 107 · 2020: 25
- FWCI
- 47.63
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- public-domain
- Locations
- MMWR Recommendations and Reports (publishedVersion, public-domain)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- seasonal influenza vaccination, influenza vaccine recommendations, inactivated influenza vaccine, live attenuated influenza vaccine, recombinant influenza vaccine, quadrivalent influenza vaccine, egg allergy, COVID-19 pandemic
- MeSH terms
- Adolescent, Adult, Aged, Centers for Disease Control and Prevention, U.S., Child, Child, Preschool, Female, Humans, Immunization Schedule, Infant, Influenza, Human, Influenza Vaccines, Male, Middle Aged, Influenza B virus, Pregnancy, Seasons, United States, Vaccines, Attenuated, Randomized Controlled Trials as Topic, Risk Assessment, Advisory Committees, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 influenza season. https://app.cochat.ai/papers/10.15585/mmwr.rr6908a1
- The paper
- Grohskopf, L. A., Alyanak, E., Broder, K. R., Blanton, L. H., Fry, A. M., Jernigan, D. B., & Atmar, R. L. (2020). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 influenza season. MMWR. Recommendations and Reports. https://doi.org/10.15585/mmwr.rr6908a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.